SCHEDULE 13D/A: The Column Group Boosts Stake in Surrozen, Inc. Through Multi-Tranche Private Placement and Warrant Restructuring

The Column Group entities and their managing partners have significantly increased their beneficial ownership in Surrozen, Inc. to up to 34% through a two-tranche private placement and a repricing of existing warrants, signaling continued investment and strategic alignment.

Summary

• The filing is an Amendment No. 4 to Schedule 13D, reporting the acquisition of additional securities in Surrozen, Inc. by The Column Group entities and managing partners.
• The Reporting Persons include The Column Group III GP, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group Opportunity III, LP, The Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, and Tim Kutzkey.
• Tim Kutzkey, a managing partner of The Column Group and a member of Surrozen's board, now beneficially owns 3,407,405 shares, representing 34% of the class.
• The Column Group III GP, LP beneficially owns 2,534,226 shares (26.8%), The Column Group III, LP owns 1,190,162 shares (13.3%), The Column Group III-A, LP owns 1,344,064 shares (15%), and The Column Group Opportunity III, LP owns 862,068 shares (9.6%).
• Surrozen, Inc. entered into a Securities Purchase Agreement on March 24, 2025, for a two-tranche private placement of Units, each consisting of one share of common stock (or pre-funded warrant) and one half of a Series E Common Warrant.
• The First Closing occurred on March 26, 2025, where 6,586,415 Units were issued, comprising 5,213,415 Shares, 1,373,000 Pre-Funded Warrants, and 3,293,207 Series E Common Warrants.
• The purchase price for Share Units was $11.60 and for Pre-Funded Warrant Units was $11.5999.
• The Second Closing involves a commitment to purchase an additional 8,499,821 Units at the same prices, contingent upon FDA clearance of the Issuer's Investigation New Drug Application for SZN-8141 by October 31, 2026, and not prior to six months and one day after the First Closing.
• All outstanding Series C and Series D common stock warrants were cancelled in connection with the Private Placement.
• The exercise price of all outstanding Series A and Series B common stock warrants was reduced to $11.54 (or $12.45 for management-held warrants).
• The Column Group entities collectively purchased 1,034,482 Units in the First Closing and subscribed for 1,551,724 Units in the Second Closing, totaling over $12 million in initial and committed investment.

Sentiment

Score: 7

Explanation: The filing indicates a significant capital raise and continued strong investor commitment from a key venture group, which are positive for the company's financial stability and development prospects. However, the warrant repricing and cancellation suggest a need to make terms more attractive, and the contingent nature of the second tranche introduces some uncertainty.

Positives

• Significant capital infusion for Surrozen, Inc. through the private placement, enhancing financial stability for ongoing operations and development.
• Continued strong commitment and increased beneficial ownership by The Column Group, a prominent venture capital investment entity, indicating confidence in the Issuer's prospects.
• Tim Kutzkey, a managing partner of The Column Group, re-joined the Issuer's board of directors, suggesting active oversight and strategic alignment between a major investor and company governance.
• The contingent nature of the second tranche, tied to FDA IND clearance for SZN-8141, provides a clear development target and a mechanism for investors to de-risk their commitment based on clinical progress.

Negatives

• The cancellation of Series C and D warrants and the repricing of Series A and B warrants suggest a need to make the investment terms more attractive, potentially reflecting a lower valuation or challenging market conditions for the Issuer.
• The repricing of warrants for management at a slightly higher exercise price ($12.45 vs. $11.54 for other investors) might be perceived negatively by some shareholders, despite being a reduction from previous terms.
• The issuance of new shares and warrants, particularly if the second tranche closes, will lead to significant dilution for existing shareholders.

Risks

• The Second Closing of the private placement, which represents a substantial portion of the committed capital, is contingent on FDA clearance of the SZN-8141 IND application by October 31, 2026; failure to achieve this milestone could impact the full capital raise.
• Purchasers have the right, but not the obligation, to purchase units in the Second Closing if the SZN-8141 program is terminated or at an Optional Closing, introducing uncertainty regarding the full capital commitment.
• Beneficial ownership limitations prevent the immediate exercise of all warrants, potentially limiting immediate capital infusion from warrant exercises.
• Failure of a Purchaser to fulfill their subscribed commitment in the Second Closing would result in the automatic cancellation of their Series E Common Warrants.

Future Outlook

The second tranche of the private placement, involving the purchase of an additional 8,499,821 units, is contingent upon the public announcement of FDA clearance for Surrozen's Investigation New Drug Application for SZN-8141 by October 31, 2026. The Issuer has also agreed to file a registration statement covering the resale of the newly issued shares and shares issuable upon warrant exercise no later than 30 calendar days following each of the closing dates, and to use reasonable best efforts to have it declared effective promptly.

Industry Context

This filing indicates a significant capital infusion into a biotechnology company, which is common for early to mid-stage biotech firms requiring substantial funding for drug development and regulatory milestones. The contingent nature of the second tranche tied to an IND clearance is a typical de-risking mechanism for investors in the biotech sector. The repricing of warrants suggests a recalibration of investor expectations or market conditions since the prior private placement, a common occurrence in the volatile biotech investment landscape.

Comparison to Industry Standards

• The two-tranche private placement structure, with the second tranche contingent on a key regulatory milestone (FDA IND clearance), is a common financing mechanism in the biotechnology industry. This allows investors to commit capital based on de-risking events, aligning investor interests with development progress.
• The repricing of warrants, while potentially dilutive, is not uncommon in the biotech sector, especially for companies facing capital needs or market valuation adjustments. It can be a necessary step to attract new investment or retain existing investor commitment by making the investment terms more favorable.
• The significant beneficial ownership by a venture capital group like The Column Group (up to 34% for Tim Kutzkey, a managing partner) is typical for early-stage or development-stage biotech companies, where venture capital firms often take substantial stakes and active board roles to guide strategic development.

Management Changes

Corporate Governance

Related Party Transactions

• The private placement involves The Column Group entities, which are related parties due to Tim Kutzkey's role as a managing partner and his re-appointment to Surrozen's board of directors.
• Warrant repricing terms for management differed slightly from other investors, with management's warrants repriced to $12.45 while other investors' warrants were repriced to $11.54.

Stakeholder Impact

• Shareholders: Potential dilution from new share issuance and warrant exercises. However, the capital raise provides crucial funding for company operations and development, which could benefit long-term value.
• Investors (The Column Group): Increased beneficial ownership and board representation, strengthening their influence and potential returns if the company performs well.
• Employees: Continued funding supports ongoing operations and potentially job security, especially for those involved in the SZN-8141 program.
• Management: Warrants held by management were also repriced, albeit at a slightly different rate, aligning their incentives with the new financing structure. Tim Kutzkey's re-appointment to the board signifies continued strategic involvement.

Next Steps

• Public announcement of FDA clearance for SZN-8141 IND application (Second Closing Milestone).
• Potential Second Closing of the private placement, contingent on the FDA milestone and timing.
• Issuer to file a registration statement covering the resale of shares and exercisable warrants within 30 calendar days of each closing.
• Issuer to use reasonable best efforts to have the registration statement declared effective within 90-120 calendar days of each closing.
• Reporting Persons may acquire or dispose of additional securities based on market conditions and other factors.

Key Dates

Recommendation

Keywords

Surrozen Inc., SEC filing, Schedule 13D, beneficial ownership, private placement, warrant repricing, Series E Common Warrants, SZN-8141, FDA IND, The Column Group, venture capital, equity investment, dilution, biotechnology, pharmaceuticals